Abstract
Since the emergence of social phobia into the diagnostic nomenclature, we have seen an exponential expansion in our knowledge regarding effective treatment of this disorder. The literature clearly supports the use of SSRIs and the SNRI venlafaxine ER as first line pharmacological agents in the treatment of GSAD. In this article, treatment studies of pharmacotherapy of social phobia are summarized. Additional issues such as comparative efficacy, treatment resistance and relapse-prevention are reviewed.
MeSH terms
-
Anticonvulsants / adverse effects
-
Anticonvulsants / therapeutic use
-
Antidepressive Agents, Second-Generation / adverse effects
-
Antidepressive Agents, Second-Generation / therapeutic use
-
Antipsychotic Agents / adverse effects
-
Antipsychotic Agents / therapeutic use
-
Benzodiazepines / adverse effects
-
Benzodiazepines / therapeutic use
-
Cyclohexanols / adverse effects
-
Cyclohexanols / therapeutic use
-
Drug Resistance
-
Humans
-
Monoamine Oxidase Inhibitors / adverse effects
-
Monoamine Oxidase Inhibitors / therapeutic use
-
Phobic Disorders / diagnosis
-
Phobic Disorders / drug therapy*
-
Phobic Disorders / psychology
-
Psychotropic Drugs / adverse effects
-
Psychotropic Drugs / therapeutic use*
-
Randomized Controlled Trials as Topic
-
Secondary Prevention
-
Selective Serotonin Reuptake Inhibitors / adverse effects
-
Selective Serotonin Reuptake Inhibitors / therapeutic use
-
Venlafaxine Hydrochloride
Substances
-
Anticonvulsants
-
Antidepressive Agents, Second-Generation
-
Antipsychotic Agents
-
Benzodiazepines
-
Cyclohexanols
-
Monoamine Oxidase Inhibitors
-
Psychotropic Drugs
-
Selective Serotonin Reuptake Inhibitors
-
Venlafaxine Hydrochloride